While it remains unclear whether the differences we observe between the sexes are due to methodological (e.g., tamoxifen pharmacology) or biological factors (e.g., frequency of tumor initiation), our findings suggest that future studies should examine and analyze males and females separately in the Ins1-/- genetic background and potentially other genetic backgrounds. This evidence concerns the gene FOXM1 and neoplasm.